Manipal Health IPO: SEBI Nod, ₹8,000 Cr Issue in 2026
SEBI clears Manipal Health’s listing plan
Manipal Health Enterprises, backed by Singapore’s Temasek, has received approval from market regulator SEBI for its proposed initial public offering, according to two sources familiar with the development cited by Reuters. The approval is a key regulatory step that allows the company to move closer to launching the IPO and finalising dates with its bankers. The development comes after Manipal filed its draft papers earlier this year as it prepared for a large fundraise in a market that has seen bouts of volatility.
Reuters reported that the hospital chain is targeting a market debut in late July or early August, based on the same sources. The information was said to be not yet public, which is why the sources asked not to be named. Separately, other IPO planning commentary in the provided material also points to a broader 2026 timeline, including references to Q3–Q4 2026 and “end-2026” depending on market conditions and clearances.
What Manipal filed with SEBI in March 2026
Manipal Health Enterprises Limited filed its Draft Red Herring Prospectus (DRHP) with SEBI on March 23, 2026. The filing positioned the company for what the material describes as India’s biggest healthcare IPO ever and, at minimum, one of the largest IPOs by an Indian healthcare company. The DRHP outlines a two-part issue structure: a fresh issue of equity and an offer-for-sale (OFS) by existing shareholders.
The proposed IPO is described as a book-built issue, with the equity shares proposed to be listed on the BSE and the NSE. The face value mentioned is ₹2 per share.
IPO size: fresh issue plus a large offer-for-sale
As per the information provided, the IPO comprises:
- A fresh issue of ₹8,000 crore
- An offer-for-sale of up to 4.32 crore shares (also stated as up to 43,227,668 equity shares in the text)
The Reuters framing also describes Manipal’s IPO filing as an offering of up to about $1.17 billion, while other parts of the material refer to a target of up to $1.2 billion. The IPO is positioned as a bet on rising demand for speciality and complex care.
Who is selling in the OFS
The OFS is described as being offered by promoters and existing shareholders. Names explicitly listed in the provided material include: Imperius Healthcare Investments Pte. Ltd, Manipal Education and Medical Group India Private Limited, TPG SG Magazine Pte. Ltd., Seventy Second Investment Company LLC, Ammar Sdn Bhd, Novo Holdings Invest Asia A/S, and Phoenix Bear Investments, LLC.
The materials also repeatedly refer to Temasek’s backing, and mention TPG in the context of the shareholder base.
How the fresh issue proceeds are proposed to be used
The DRHP-linked summaries specify three stated uses for the net proceeds from the fresh issue:
- Repayment or prepayment of outstanding borrowings and accrued interest availed by Manipal Hospitals Private Limited
- Acquisition of a minority stake in the step-down subsidiary Sahyadri Hospitals Private Limited
- General corporate purposes
A more granular allocation is also provided in the text and transcript-style excerpt:
- ₹5,378 crore towards debt repayment
- ₹574 crore towards acquiring a minority stake in Sahyadri Hospitals
Timeline: late July–early August vs broader 2026 window
Reuters sources said the company is targeting a listing in late July or early August. Other references in the provided material indicate that issuers often launch 4–6 months after SEBI approval, which is framed as a likely Q3–Q4 2026 window. There is also mention that, subject to market conditions, the plan is to launch by end-2026.
Taken together, the provided text indicates that the company is working within a 2026 timeline, with some reporting pointing to a nearer-term debut and other references leaving room for a later launch depending on conditions.
Valuation expectations cited in the filings commentary
The material references a targeted valuation of roughly $12 billion (about ₹1,00,000 crore). Another excerpt states Manipal may be targeting a valuation of up to $13 billion. These figures are presented as targets or expectations in the surrounding IPO commentary.
One section also notes that, at the targeted valuation, the listing could surpass Max Healthcare to make Manipal India’s most valuable hospital operator. That comparison is presented in the supplied text as an implication of the valuation target.
Banking syndicate and other key intermediaries
The book-running lead managers listed across the material are:
- Kotak Mahindra Capital Company Limited
- Axis Capital Limited
- Goldman Sachs (India) Securities Private Limited
- Jefferies India Private Limited
- J.P. Morgan India Private Limited
- UBS Securities India Private Limited
- DBS Bank India Limited
KFin Technologies Limited is named as the registrar to the issue.
Key facts at a glance
Market context and why the IPO is being watched
The Reuters summary describes an IPO being prepared in a period of volatile domestic equities, fragile global sentiment, geopolitical uncertainty, and foreign sell-offs. Against that backdrop, Manipal’s proposed IPO is being positioned as a large healthcare listing tied to demand for speciality and complex care.
The size of the fresh issue, the scale of the OFS, and the high-profile syndicate of banks are among the reasons the transaction is being framed as a landmark healthcare offering. The stated use of proceeds also highlights balance sheet objectives, with a large portion directed to debt reduction.
What to track next
The exact IPO dates are expected to be confirmed in the Red Herring Prospectus (RHP), as indicated in the provided material. Investors will also track whether the company proceeds with any pre-IPO placement of up to ₹1,600 crore, since that could reduce the size of the fresh issue. Further updates on timing will likely depend on market conditions and the company’s final decision on the launch window.
Frequently Asked Questions
Did your stocks survive the war?
See what broke. See what stood.
Live Q4 Earnings Tracker
